Inovio 
Welcome,         Profile    Billing    Logout  
 27 Products   14 Diseases   27 Products   13 Trials   837 News 


123456789»
  • ||||||||||  neoantigen DNA vaccine / Washington University School of Medicine in St. Louis, AstraZeneca
    Trial completion date:  Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov) -  Mar 12, 2024   
    P1,  N=9, Active, not recruiting, 
    Trial completion date: Dec 2023 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024 Trial completion date: Dec 2023 --> Dec 2024
  • ||||||||||  Review, Journal:  A Review of Clinical Trials of Cancer and Its Treatment as a Vaccine. (Pubmed Central) -  Nov 13, 2023   
    Trial completion date: Dec 2023 --> Dec 2024 This brief discussion of vaccines and their varieties with examples also discusses vaccine clinical trials in relation to cancer diseases in this DNA and RNA-based cancer vaccine that has had successful clinical trials like the cervical cancer drug VGX-3100, the kidney cancer drug Pembrolizumab, MGN-1601, the prostate cancer drug pTVG-HP with rhGM-CSF, the melanoma cancer drug proteasome siRNA, and the lung cancer drug FRAME-001.
  • ||||||||||  INO-3107 / Inovio
    P1/2 data, Journal:  Interim Results of a Phase 1/2 Open-Label Study of INO-3107 for HPV-6 and/or HPV-11-Associated Recurrent Respiratory Papillomatosis. (Pubmed Central) -  Oct 22, 2023   
    P1/2
    This brief discussion of vaccines and their varieties with examples also discusses vaccine clinical trials in relation to cancer diseases in this DNA and RNA-based cancer vaccine that has had successful clinical trials like the cervical cancer drug VGX-3100, the kidney cancer drug Pembrolizumab, MGN-1601, the prostate cancer drug pTVG-HP with rhGM-CSF, the melanoma cancer drug proteasome siRNA, and the lung cancer drug FRAME-001. The data suggest that INO-3107 administered by IM/EP is tolerable and immunogenic and provides clinical benefit to adults with RRP.
  • ||||||||||  AZD8076 / AstraZeneca, Inovio, AZD5396 / Inovio, AstraZeneca
    Enrollment open, Enrollment change, Trial completion date, Trial primary completion date:  dMAbs for Prevention of COVID-19 (clinicaltrials.gov) -  Sep 21, 2023   
    P1,  N=39, Recruiting, 
    Active, not recruiting --> Completed | Trial completion date: Jul 2023 --> Dec 2022 | Trial primary completion date: Jul 2023 --> Dec 2022 Active, not recruiting --> Recruiting | N=26 --> 39 | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025
  • ||||||||||  zenuzolac (VGX-1027) / GeneOne
    Trial completion date:  GLS-1027 for the Prevention of Severe Pneumonitis Caused by SARS-CoV-2 Infection (COVID-19) (clinicaltrials.gov) -  Sep 13, 2023   
    P2,  N=132, Active, not recruiting, 
    Active, not recruiting --> Recruiting | N=26 --> 39 | Trial completion date: Sep 2024 --> Sep 2025 | Trial primary completion date: Sep 2024 --> Sep 2025 Trial completion date: Jun 2023 --> Dec 2023
  • ||||||||||  Covovax (NVX-CoV2373) / Novavax, Takeda, Serum Institute of India
    Review, Journal:  Vaccination is the most effective and best way to avoid the disease of COVID-19. (Pubmed Central) -  Sep 3, 2023   
    Among the vaccines that stimulate the host's immune system with the help of DNA are: undergoing Phase 2/3 trials including INO-4800 (International Vaccine Institute; Inovio Pharmaceuticals), Symvivo, Canada-COVID19 (AnGes, Inc.); GX-19 (Genexine, Inc.). BNT162b2
  • ||||||||||  GNOS-PV02 / Geneos Therap
    Enrollment closed, Trial completion date, Combination therapy, Metastases:  GT-30: GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC (clinicaltrials.gov) -  Jun 15, 2023   
    P1/2,  N=36, Active, not recruiting, 
    The low ORR among patients with cervical cancer led to study discontinuation despite a clinically meaningful disease control rate. Recruiting --> Active, not recruiting | Trial completion date: Aug 2023 --> Jun 2025
  • ||||||||||  bizalimogene ralaplasmid (VGX-3100) / Inovio
    Trial completion date, Trial primary completion date:  VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions (clinicaltrials.gov) -  Jun 7, 2023   
    P2,  N=80, Recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Aug 2023 --> Jun 2025 Trial completion date: May 2024 --> Sep 2029 | Trial primary completion date: May 2024 --> Sep 2029
  • ||||||||||  INO-4500 / Inovio, EBS-Lassa / Emergent Biosolutions
    Review, Journal:  Lassa fever vaccine candidates: A scoping review of vaccine clinical trials. (Pubmed Central) -  Jun 5, 2023   
    Trial completion date: May 2024 --> Sep 2029 | Trial primary completion date: May 2024 --> Sep 2029 Though LF vaccine development is still in early stages, current progress towards a safe and effective vaccine is encouraging.
  • ||||||||||  INO-4700 / GeneOne, Inovio, ChAdOx1 MERS / J&J, University of Oxford
    Journal:  Safety and immunogenicity of the ChAdOx1, MVA-MERS-S, and GLS-5300 DNA MERS-CoV vaccines. (Pubmed Central) -  Apr 25, 2023   
    Trial completion date: Apr 2023 --> Dec 2023 The findings showed that high doses of current MERS-CoV vaccine candidates conferred better immunogenicity than low doses and that there were no differences in the safety of the vaccines.
  • ||||||||||  AZD8076 / AstraZeneca, Inovio, AZD5396 / Inovio, AstraZeneca
    Enrollment closed, Trial completion date, Trial primary completion date:  dMAbs for Prevention of COVID-19 (clinicaltrials.gov) -  Apr 21, 2023   
    P1,  N=26, Active, not recruiting, 
    The findings showed that high doses of current MERS-CoV vaccine candidates conferred better immunogenicity than low doses and that there were no differences in the safety of the vaccines. Recruiting --> Active, not recruiting | Trial completion date: Nov 2023 --> Sep 2024 | Trial primary completion date: Nov 2023 --> Sep 2024
  • ||||||||||  Review, Journal:  Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19). (Pubmed Central) -  Apr 4, 2023   
    Intracellular delivery of nucleic acid-based vaccines and their adverse events needs further research. Considering re-emergence of the COVID-19 variants of concern, vaccine reassessment and the development of polyvalent vaccines, or pan-coronavirus strategies, is essential for effective infection prevention.
  • ||||||||||  MEDI0457 / AstraZeneca, Avastin (bevacizumab) / Roche
    Survival benefit to immunotherapy according to site of organ involvement in metastatic anal cancer. (On Demand | Level 1, West Hall; Poster Board No. A7) -  Dec 13, 2022 - Abstract #ASCOGI2023ASCO_GI_676;    
    These data provide historical context in estimating median PFS necessary for future trial design in patients with metastatic anal cancer. Lymph node-only distribution of distant metastatic disease was predictive for improved survival with immunotherapy.
  • ||||||||||  INO-4700 / GeneOne, Inovio
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Safety, Tolerability and Immunogenicity of INO-4700 for MERS-CoV in Healthy Volunteers (clinicaltrials.gov) -  Nov 21, 2022   
    P2,  N=192, Active, not recruiting, 
    While the primary efficacy endpoint was not reached, clinical benefit was encouraging. Recruiting --> Active, not recruiting | N=542 --> 192 | Trial completion date: Jun 2024 --> Nov 2022 | Trial primary completion date: Jun 2024 --> Nov 2022
  • ||||||||||  INO-4800 / Inovio, The Wistar Institute, INO-9112 / Inovio
    Enrollment change, Trial withdrawal, Combination therapy:  Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers (clinicaltrials.gov) -  Nov 17, 2022   
    P1,  N=0, Withdrawn, 
    Recruiting --> Active, not recruiting | N=542 --> 192 | Trial completion date: Jun 2024 --> Nov 2022 | Trial primary completion date: Jun 2024 --> Nov 2022 N=160 --> 0 | Not yet recruiting --> Withdrawn
  • ||||||||||  INO-A002 / Inovio
    Trial completion:  A Study of INO-A002 in Healthy Dengue Virus-naive Adults (clinicaltrials.gov) -  Nov 8, 2022   
    P1,  N=30, Completed, 
    Active, not recruiting --> Completed | Trial primary completion date: May 2022 --> Oct 2022 Active, not recruiting --> Completed
  • ||||||||||  neoantigen DNA vaccine / Washington University School of Medicine in St. Louis, AstraZeneca
    Enrollment closed, Trial completion date, Trial primary completion date:  Neoantigen-based Personalized DNA Vaccine in Patients With Newly Diagnosed, Unmethylated Glioblastoma (clinicaltrials.gov) -  Oct 21, 2022   
    P1,  N=9, Active, not recruiting, 
    Active, not recruiting --> Completed Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Apr 2023 | Trial primary completion date: Dec 2023 --> May 2022
  • ||||||||||  INO-4800 / Inovio, The Wistar Institute
    Enrollment change, Trial completion date, Trial termination, Trial primary completion date:  INNOVATE: Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure (clinicaltrials.gov) -  Oct 13, 2022   
    P2/3,  N=1308, Terminated, 
    Recruiting --> Active, not recruiting | Trial completion date: Nov 2024 --> Apr 2023 | Trial primary completion date: Dec 2023 --> May 2022 N=7517 --> 1308 | Trial completion date: Feb 2023 --> Sep 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2023 --> Sep 2022; The study was terminated to prioritize Inovio's COVID-19 efforts to advance a heterologous booster strategy and optimize potential impact on global public health.
  • ||||||||||  rocakinogene sifuplasmid (INO-9012) / Inovio, INO-5401 / Inovio
    Trial completion date, Trial primary completion date, Combination therapy, Metastases:  INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma (clinicaltrials.gov) -  Oct 12, 2022   
    P1/2,  N=35, Active, not recruiting, 
    N=7517 --> 1308 | Trial completion date: Feb 2023 --> Sep 2022 | Active, not recruiting --> Terminated | Trial primary completion date: Feb 2023 --> Sep 2022; The study was terminated to prioritize Inovio's COVID-19 efforts to advance a heterologous booster strategy and optimize potential impact on global public health. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
  • ||||||||||  INO-4500 / Inovio
    Trial completion, Combination therapy:  Dose-ranging Study: Safety, Tolerability and Immunogenicity of INO-4500 in Healthy Volunteers in Ghana (clinicaltrials.gov) -  Oct 3, 2022   
    P1,  N=220, Completed, 
    While neither cohort A nor C were expanded due to insufficient clinical activity, the clinical responses seen with SBRT/FLT3L/polyICLC/nivolumab suggest sufficient clinical benefit that may warrant additional investigation, particularly the contribution of radiation to the responses observed. Active, not recruiting --> Completed
  • ||||||||||  INO-4800 / Inovio, The Wistar Institute, INO-9112 / Inovio
    Trial completion date, Trial primary completion date, Combination therapy:  Safety, Tolerability and Immunogenicity of INO-4800 for COVID19 in Healthy Volunteers (clinicaltrials.gov) -  Aug 22, 2022   
    P1,  N=160, Not yet recruiting, 
    Recruiting --> Active, not recruiting | Trial completion date: Mar 2023 --> Oct 2022 Trial completion date: Aug 2023 --> Mar 2024 | Trial primary completion date: Aug 2023 --> Mar 2024
  • ||||||||||  INO-4800 / Inovio, The Wistar Institute
    INO-4800 ? (Twitter) -  Aug 20, 2022